Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Recently, we reported rifabutin hyperactivity against We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic and , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097462 | PMC |
| http://dx.doi.org/10.1128/AAC.02204-20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibiotic Treatment of Carbapenem-Resistant Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence.
Antibiotics (Basel)
May 2024
Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, 'Magna Graecia' University of Catanzaro, 88100 Catanzaro, Italy.
Article Synopsis
- * Sulbactam/durlobactam and cefiderocol are promising candidates for treating these infections, while colistin should only be a last-resort option due to safety concerns.
- * There is a need for randomized clinical trials to evaluate new therapy combinations and the effectiveness of certain antibiotics as partners in treatment regimens for CRAB infections.
Comparison of in vitro synergy between polymyxin B or colistin in combination with 16 antimicrobial agents against multidrug-resistant Acinetobacter baumannii isolates.
J Microbiol Immunol Infect
April 2024
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 3
Article Synopsis
- * Researchers conducted chequerboard assays on 50 clinical strains to assess drug combinations, finding that most combinations were effective or synergistic, with very few showing antagonism.
- * The results indicated strong synergistic effects of POLB and COL with rifabutin, rifampicin, and rifapentine, suggesting these combinations could be used effectively in treating MDR-AB infections.
Activity of Drug Combinations against Grown in Aerobic and Hypoxic Conditions.
Microorganisms
July 2022
Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.
Infections caused by Mycobacterium abscessus (Mab), an environmental non-tuberculous mycobacterium, are difficult to eradicate from patients with pulmonary diseases such as cystic fibrosis and bronchiectasis even after years of antibiotic treatments. In these people, the low oxygen pressure in mucus and biofilm may restrict Mab growth from actively replicating aerobic (A) to non-replicating hypoxic (H) stages, which are known to be extremely drug-tolerant. After the exposure of Mab A and H cells to drugs, killing was monitored by measuring colony-forming units (CFU) and regrowth in liquid medium (MGIT 960) of 1-day-old A cells (A1) and 5-day-old H cells (H5).
View Article and Find Full Text PDFSynergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.
Antimicrob Agents Chemother
March 2021
Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA
Recently, we reported rifabutin hyperactivity against We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic and , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant infections.
View Article and Find Full Text PDFIn vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.
J Antimicrob Chemother
December 2020
BioVersys AG, Basel, Switzerland.
Background: Rifabutin, an oral drug approved to treat Mycobacterium avium infections, demonstrated potent activity against Acinetobacter baumannii in nutrient-limited medium enabled by rifabutin cellular uptake through the siderophore receptor FhuE.
Objectives: To determine rifabutin in vitro activity and resistance mechanisms in a large panel of A. baumannii isolates.